Clinical Trials on Oligometastatic Lung Adenocarcinoma

Total 63639 results

First Affiliated Hospital Bengbu Medical College

Recruiting

A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Adenocarcinoma of the Stomach | Adenocarcinoma - GEJ

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
AstraZeneca

Completed

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology (ICAN)

Non-Small Cell Lung Cancer

China
Kunming Medical University

Terminated

CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

Gastroesophageal Junction Adenocarcinoma | Stage IB Esophageal Adenocarcinoma AJCC v7 | Stage II Esophageal Adenocarcinoma AJCC v7 | Stage IIA Esophageal Adenocarcinoma AJCC v7 | Stage IIB Esophageal Adenocarcinoma AJCC v7 | Stage IIIA Esophageal Adenocarcinoma AJCC v7 | Stage IIIB Esophageal...

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Adenocarcinoma | NSCLC | Squamous Cell Carcinoma
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditions

United States
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (S-1 adjuvant)

Adenocarcinoma,Stomach | Adenocarcinoma, Esophagogastric Junction

Germany
Blood Transfusion Centre of Slovenia

Unknown

Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma (SYSTHER)

Pancreatic Tubular Adenocarcinoma

Slovenia
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Akeso

Active, not recruiting

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Samsung Medical Center

Unknown

Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of
Baylor Research Institute

Not yet recruiting

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Adenocarcinoma

United States
Essentia Health

Terminated

Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

Ductal Adenocarcinoma of Pancreas | Adenocarcinoma of Ampulla

United States
AstraZeneca

Completed

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma (MUTACT)

Non Small Cell Lung Cancer

France
MaxCyte, Inc.
CTI Clinical Trial and Consulting Services

Terminated

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Fallopian Tube Adenocarcinoma | Peritoneal Mesothelioma | Primary Peritoneal Carcinoma | Adenocarcinoma of the Ovary

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
University of Southern California
National Cancer Institute (NCI); Ipsen

Withdrawn

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric Adenocarcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

Adenocarcinoma of the Gastroesophageal Junction | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma

United States
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

China, Korea, Republic of, Thailand
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital

Completed

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Adenocarcinoma of Stomach | Adenocarcinoma of GE Junction | Adenocarcinoma of Esophagus

United States
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Fudan University

Recruiting

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC (LEO)

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Phanes Therapeutics
Merck Sharp & Dohme LLC

Recruiting

PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

Pancreatic Ductal Adenocarcinoma | Gastric or Gastroesophageal Junction Adenocarcinoma

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Incyte Corporation

Recruiting

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (AuspiCiOus)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

Netherlands
Weill Medical College of Cornell University
Sanofi

Withdrawn

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Pancreatic Adenocarcinoma | Metastatic... and other conditions

United States
Celgene

Completed

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

Adenocarcinoma | Carcinoma | Non-Small Cell Lung Cancer | Carcinoma, Large Cell | Squamous Cell Carcinoma | Lung Neoplasm

United States
Royal Marsden NHS Foundation Trust
Eli Lilly and Company; AstraZeneca; Clovis Oncology, Inc.; MedImmune LLC

Recruiting

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM)

Adenocarcinoma of the Stomach | Adenocarcinoma of the Oesophagus | Adenocarcinoma of the Gastro-oesophageal Junction

United Kingdom
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (ELEMENT)

Non-Squamous Non-Small Cell Lung Cancer

Serbia
Sun Yat-sen University

Completed

A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung

Non-small Cell Lung Cancer

China
National Cancer Institute (NCI)

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma... and other conditions

United States
Lawson Health Research Institute
London Health Sciences Foundation

Not yet recruiting

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma (ANSR-PDAC)

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
Institut National d'Oncologie, Morocco

Completed

Audit of Surgery for Colorectal Cancer (AuditCR)

Rectal Adenocarcinoma | Colon Adenocarcinoma

Morocco
Rain Oncology Inc

Terminated

Milademetan in Advanced/Metastatic Solid Tumors

Melanoma | Sarcoma | Cervical Cancer | Testicular Germ Cell Tumor | Gastric Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Lung Adenocarcinoma | Solid Tumors | Pancreas Cancer | Head and Neck Carcinoma | Biliary Tract Cancer | Ovarian Carcinoma | Adrenocortical Carcinoma | Bladder Urothelial Carcinoma | Breast... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Intraperitoneal Paclitaxel | Metastatic Appendiceal Adenocarcinoma

United States
Fudan University

Unknown

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Stage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic Adenocarcinoma

China
University of Oklahoma
ImmunoGen, Inc.

Withdrawn

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Jean-Luc Van Laethem
Celgene Corporation

Completed

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer (NEOPAX-001)

Pancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally Advanced

Belgium
European Organisation for Research and Treatment...
Merck Sharp & Dohme LLC; Swiss Group for Clinical Cancer Research

Not yet recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg)

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
University Ghent
University Hospital, Geneva

Active, not recruiting

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Metastatic | Oligometastatic Cancer

Norway, Spain, Belgium, Switzerland, Australia, Italy

Clinical Trials on Oligometastatic Lung Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations